Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

ClinicalTrials.gov ID: NCT00863798

Public ClinicalTrials.gov record NCT00863798. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 24, 2026, 12:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder

Study identification

NCT ID
NCT00863798
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Enrollment
682 participants

Conditions and interventions

Interventions

  • Desvenlafaxine Succinate Sustained-Release 10mg Drug
  • Desvenlafaxine Succinate Sustained-Release 50 mg Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2009
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010
Last update posted
May 5, 2011

2009 – 2010

United States locations

U.S. sites
24
U.S. states
13
U.S. cities
24
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35216
Pfizer Investigational Site Encino California 91316
Pfizer Investigational Site Newport Beach California 92660
Pfizer Investigational Site Redlands California 92374
Pfizer Investigational Site Upland California 91786
Pfizer Investigational Site Aurora Colorado 80045
Pfizer Investigational Site Denver Colorado 80204
Pfizer Investigational Site Cromwell Connecticut 06416
Pfizer Investigational Site Maitland Florida 32751
Pfizer Investigational Site North Miami Florida 33161
Pfizer Investigational Site South Miami Florida 33143
Pfizer Investigational Site Indianapolis Indiana 46260
Pfizer Investigational Site St Louis Missouri 63139
Pfizer Investigational Site New York New York 10128
Pfizer Investigational Site Staten Island New York 10312
Pfizer Investigational Site Toledo Ohio 43623
Pfizer Investigational Site Eugene Oregon 97401
Pfizer Investigational Site Portland Oregon 97210
Pfizer Investigational Site Salem Oregon 97301
Pfizer Investigational Site Media Pennsylvania 19063
Pfizer Investigational Site Herndon Virginia 20170
Pfizer Investigational Site Midlothian Virginia 23112
Pfizer Investigational Site Middleton Wisconsin 53562
Pfizer Investigational Site Waukesha Wisconsin 53188

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00863798, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2011 · Synced Apr 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00863798 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →